Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NZD4
UPID:
AHSP_HUMAN
Alternative names:
Erythroid differentiation-related factor; Erythroid-associated factor
Alternative UPACC:
Q9NZD4; Q8TD01
Background:
Alpha-hemoglobin-stabilizing protein, also known as Erythroid differentiation-related factor or Erythroid-associated factor, plays a crucial role in erythroid cell development. It acts as a chaperone to prevent the harmful aggregation of alpha-hemoglobin, specifically protecting free alpha-hemoglobin from precipitation. This protein is essential for maintaining the balance of hemoglobin components during red blood cell formation.
Therapeutic significance:
Understanding the role of Alpha-hemoglobin-stabilizing protein could open doors to potential therapeutic strategies. Its ability to modulate pathological states of alpha-hemoglobin excess, such as beta-thalassemia, highlights its potential as a target for therapeutic intervention in hemoglobinopathies.